Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatme...
Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA
VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML ( Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA )
27 Jan 2020
Patient quality of life in adult ALL
Zack Pemberton-Whiteley (UK)
Patient quality of life in adult ALL ( Zack Pemberton-Whiteley (UK) )
23 Jan 2020
CAR-T cell therapy for ALL: Current challenges and future approaches
Dr Sara Ghorashian - University College London, London, UK
CAR-T cell therapy for ALL: Current challenges and future approaches ( Dr Sara Ghorashian - University College London, London, UK )
23 Jan 2020
Considerations for treatment sequencing in B-ALL
Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany
Considerations for treatment sequencing in B-ALL ( Prof Nicola Gökbuget - Universitätsklinikum Frankfurt, Frankfurt, Germany )
23 Jan 2020
CART-T cell therapy in young patients with relapsed/refractory ALL
Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany
CART-T cell therapy in young patients with relapsed/refractory ALL ( Prof Peter Bader - Universitätsklinikum Frankfurt, Frankfurt, Germany )
23 Jan 2020
HSCT: Donor selection for patients with ALL
Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwic...
HSCT: Donor selection for patients with ALL ( Prof Sebastian Giebel - The Maria Skłodowska-Curie Institute of Oncology, Gliwice, Poland )
23 Jan 2020
Therapy of Ph-positive adult ALL
Prof Oliver Ottmann - Cardiff University, Cardiff, UK
Therapy of Ph-positive adult ALL ( Prof Oliver Ottmann - Cardiff University, Cardiff, UK )
23 Jan 2020
The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Defining the role of immunotherapy in B-cell ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )
23 Jan 2020
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
How is minimal residual disease managed in patients with ALL? ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020